Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 8/20 | 0.36 |
| ▸ | GNPAT | O15228 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.35 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30839281 | 0.98 | PTPN1 (0.41) | PTPN1NAALAD2FOLH1RIMKLABACE1 | |
| SCHEMBL30770813 | 0.96 | BACE1 (0.40) | PTPN1NAALAD2BACE1BACE2CTSD | |
| SCHEMBL29842532 | 0.93 | NAALAD2 (0.38) | NAALAD2FOLH1RIMKLABACE1BACE2 | |
| SCHEMBL30692040 | 0.93 | NAALAD2 (0.38) | NAALAD2FOLH1RIMKLASLC15A2HPGD | |
| SCHEMBL31757521 | 0.92 | NAALAD2 (0.38) | NAALAD2FOLH1RIMKLABACE1SLC15A2 | |
| SCHEMBL31757519 | 0.92 | NAALAD2 (0.38) | NAALAD2FOLH1RIMKLABACE1SLC15A2 | |
| SCHEMBL38651064 | 0.92 | NAALAD2 (0.38) | NAALAD2FOLH1RIMKLABACE1SLC15A2 | |
| SCHEMBL31757514 | 0.92 | BACE1 (0.39) | NAALAD2FOLH1RIMKLABACE1BACE2 | |
| SCHEMBL30477909 | 0.92 | MME (0.37) | PTPN1BACE1GNPATBACE2SLC15A2 | |
| SCHEMBL30668193 | 0.92 | MME (0.36) | BACE1SLC15A2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279622-A1 | COELENTERAZINE-UTILIZING LUCIFERASES WITH STABLE GLOW-TYPE LIGHT EMISSION AND METHODS OF PRODUCING AND USING THEREOF | MASARYKOVA UNIVERZITA (CZ) | 2024-08-22 | — | — | US | disclosed |
| EP-4137567-A1 | COELENTERAZINE-UTILIZING LUCIFERASES WITH STABLE GLOW-TYPE LIGHT EMISSION, INCREASED SUBSTRATE AFFINITY, SUPPRESED PRODUCT INHIBITION, AND MODULATED EMISSION WAVELENGTHS, AND METHODS OF PRODUCING AND USING THEREOF | Masarykova Univerzita (CZ) | 2023-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279622-A1 | COELENTERAZINE-UTILIZING LUCIFERASES WITH STABLE GLOW-TYPE LIGHT EMISSION AND METHODS OF PRODUCING AND USING THEREOF | RNGTT, GPKOW, LUC7L2 | PTPN1 3529/4885NAALAD2 824/4885FOLH1 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.